New & Improved!

Submit a New & Noteworthy
April 2018
Response to Market Shortages
By: QuVa Pharma, Inc

As an emerging leader in 503B compounding outsourcing, QuVa Pharma has responded to market demands with increased capability and capacity. Its cGMP ability to produce sterile-to-sterile and API-to-sterile products increases available, safe options for health care providers during times of chronic shortages. QuVa Pharma now has three FDA-registered 503B sterile compounding facilities (two in Texas
and one in New Jersey), and an anticipated 90,000 square-feet of additional space as of Q4 2018.

Click here to view product detail on Findit.

Current Issue

Enter our Sweepstakes now for your chance to win the following prizes:

    Just answer the following quick question for your chance to win:

    To continue, you must either login or register: